TRANSGENE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.21 EUR | -5.47% |
|
-12.45% | -11.68% |
| 10/04 | Transgene: presents vaccine results at AACR | CF |
| 28/03 | Transgene CFO Steps Down; Successor Assumes Office | MT |
| Sales 2023 | 7.9M 8.45M 705M | Sales 2024 * | 39.8M 42.55M 3.55B | Capitalization | 122M 130M 10.85B |
|---|---|---|---|---|---|
| Net income 2023 | -22M -23.52M -1.96B | Net income 2024 * | -13M -13.9M -1.16B | EV / Sales 2023 | 17.6 x |
| Net Debt 2023 | 1.63M 1.74M 145M | Net Debt 2024 * | 16.4M 17.54M 1.46B | EV / Sales 2024 * | 3.47 x |
| P/E ratio 2023 |
-6.23
x | P/E ratio 2024 * |
-8.64
x | Employees | 143 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 34.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on Transgene
More press releases
More news
| 1 day | -5.47% | ||
| 1 week | -12.45% | ||
| Current month | +6.14% | ||
| 1 month | +9.01% | ||
| 3 months | -7.35% | ||
| 6 months | -11.68% | ||
| Current year | -11.68% |
1 week
1.18
1.35
1 month
1.111.52
Current year
1.031.52
1 year
1.032.55
3 years
1.033.15
5 years
0.813.39
10 years
0.8111.15
| Managers | Title | Age | Since |
|---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 31/22/31 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 01/16/01 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 17/16/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 19/13/19 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 01/91/01 |
| Director/Board Member | 63 | 07/04/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.21 | -5.47% | 74,243 |
| 25/24/25 | 1.28 | -4.90% | 50,816 |
| 24/24/24 | 1.346 | +1.82% | 12,204 |
| 23/24/23 | 1.322 | -0.60% | 15,316 |
| 22/24/22 | 1.33 | -3.76% | 43,299 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology.
Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.
Calendar
14/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.21
EUR
Average target price
3.5
EUR
Spread / Average Target
+189.26%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.68% | 130M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TNG Stock
